Brief: Upstream Bio Reports Positive Top-Line Results From The Phase 2 Vibrant Trial Of Verekitug For The Treatment Of Chronic Rhinosinusitis With Nasal Polyps (Crswnp)
02/09/2025 11:42
Upstream Bio Inc UPB.O: UPSTREAM BIO REPORTS POSITIVE TOP-LINE RESULTS FROM THE PHASE 2 VIBRANT TRIAL OF VEREKITUG FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) UPSTREAM BIO INC - VEREKITUG MEETS PRIMARY AND SECONDARY ENDPOINTS IN PHASE 2 TRIAL UPSTREAM BIO INC: NO SERIOUS ADVERSE EVENTS (SAES) OBSERVED; GENERALLY WELL TOLERATED SAFETY PROFILE CONSISTENT WITH PREVIOUS STUDIES Source text: ID:nGNX6mzyj2 Further company coverage: UPB.O
Recent news on Upstream Bio
See all newsUpstream Bio Q2 net loss narrows slightly on lower R&D costs
Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio Q1 net loss widens on higher R&D costs